Sign in
GRCE Stock Price, Chart, Stats & News
Grace Therapeutics, Inc.
Save
Grace Therapeutics, Inc. (GRCE) does not currently pay a dividend.
34.83M
Market cap
–
Current P/E
2.17x
Forward P/E
GRCE chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | 12.95% |
ROA | -9.99% |
ROE | -10.61% |
D/E | – |
Interest coverage ratio | – |
GRCE valuation
P/E | – |
P/S | – |
P/B | 1.22x |
P/CF | -7.81x |
P/FCF | -6.51x |
P/OCF | -7.81x |
PEG | -0.39x |
EV multiple | -10.91x |
About
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia.
Similar securities
Based on sector and market capitalization
Report issue